瑞舒伐他汀钙联合曲美他嗪治疗急性冠脉综合征的临床疗效观察

目的观察瑞舒伐他汀钙联合曲美他嗪治疗急性冠脉综合征的临床疗效。方法将79例急性冠脉综合征患者随机分为对照组和治疗组。对照组给予常规治疗和曲美他嗪治疗,治疗组在此治疗基础上加用瑞舒伐他汀钙,总治疗疗程12周。比较两组患者血脂、超敏C-反应蛋白（high sensitivity C-reactive protein,hs-CRP）及冠心病缓解有效率。结果①治疗组患者经12周上述药物治疗,甘油三酯（triglyceride,TG）、总胆固醇（total cholesterol,TC）、低密度胆固醇脂蛋白（low density lipoprotein cholesterol,LDL-C）较治疗前减低,差异具有统计学意义（P〈0.05）;治疗12周后,治疗组较对照组患者TC、TG、LDL-C低。差异具有统计学意义（P〈0.05）;②治疗组患者经12周上述药物治疗,CRP值较治疗前减低,差异具有统计学意义（P〈0.05）;治疗12周后,治疗组患者CRP值较对照组低,差异具有统计学意义（P〈0.05）;③治疗组总有效率（87.5%）明显高于对照组（76.9%）（P〈0.05）,差异具有统计学意义（P〈0.05）。结论瑞舒伐他汀钙联合曲美他嗪治疗急性冠脉综合征疗效较好,不良反应轻微。

Effects of Rosuvastatain plus Trimetazidine on patients with acute coronary syndrome

【Objective】To observe effects of rosuvastatain plus trimetazidine on patients with acute coronary syndrome.【Methods】79 patients with acute coronary syndrome were randomLy divided into two groups,A group(conventional therapy+ trimetazidine) and B group(conventional therapy+ trimetazidine+ rosuvastatain).The treatment lasted for 12 weeks.Compare serum blood lipid,high sensitivity C-reactive protein(hs-CRP) and the efficiency of remission of coronary heart disease before and after treatment in A group to B group.【Resluts】 After treatment for 12 weeks,triglyceride(TG)、total cholesterol(TC)、low density lipoprotein cholesterol(LDL-C)、hs-CRP in B groups were decreased(P<0.05).After treatment for 12 weeks,TG、TC、LDL-C、hs-CRP in B groups were lower compare to A group((P<0.05).The efficiency of remission of coronary heart disease in B group was better than A group.【Conclusion】Effects of rosuvastatain plus trimetazidine on patients with acute coronary syndrome are high and adverse reactions are little.